Studies by Khan and Zhang have demonstrated that pharmacological inhibition of SIRT1 restores p53 and NF-κB acetylation, enhances immune infiltration, reduces metastatic spread, and sensitizes NSCLC cells to chemotherapy [105]. This evidence concerns the gene SIRT1 and non-small cell lung carcinoma.